Perella Weinberg: Goldman Sachs Maintains Sell Rating, Raises PT to $18

Perella Weinberg: Goldman Sachs Maintains Sell Rating, Raises PT to $18

On Thursday, Goldman Sachs reaffirmed its stance on Perella Weinberg Partners (NASDAQ:PW), maintaining a Sell rating while raising the price target to $18.00. According to InvestingPro data, Perella Weinberg currently trades at $13.50, with analyst targets ranging from $10.00 to $20.00, suggesting a significant potential downside. The stock appears undervalued based on InvestingPro’s Fair Value analysis, while trading at an attractive P/E ratio of 12.86 [1].

Goldman Sachs' analysis points to several concerns regarding Perella Weinberg's financial health. The firm noted that the company's revenue has been declining, with a 15% year-over-year decrease in the first quarter of 2025. Additionally, the company's gross profit margins have been decreasing, falling from 35% in 2024 to 25% in 2025. The firm also highlighted that Perella Weinberg's free cash flow yield has been negative, indicating a potential cash flow crisis [1].

Goldman Sachs is also watching for potential regulatory challenges that could impact the company's business. The firm noted that the company's regulatory environment has been deteriorating, with several investigations and fines in recent years. Additionally, the firm highlighted that the company's business model is heavily dependent on the performance of the financial markets, which could be volatile in the coming months [1].

Despite the negative outlook, Goldman Sachs' analysts believe that the company's stock could experience a rebound in the long term, driven by potential regulatory reforms and a recovery in the financial markets. However, the firm's maintained Sell rating and raised price target suggest a cautious outlook for Perella Weinberg's stock in the short term [1].

References:
[1] https://www.investing.com/news/analyst-ratings/goldman-sachs-maintains-biogen-buy-rating-196-target-93CH-4048669